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OBJECTIVES: To examine the effectiveness of a quality
improvement program to decrease prescribing of high-risk
medications.
DESIGN: Single cohort, pre- and postintervention.
SETTING: Regional network of Department of Veterans
Affairs medical facilities.
PARTICIPANTS: Outpatient veterans aged 65 and older
who received one or more high-risk medications and the
prescribing clinicians.
INTERVENTION: A two-stage intervention was imple-
mented. First, a real-time warning message to prescribers
appeared whenever one of the high-risk drugs was ordered;
second, a personally addressed letter from the Chief Med-
ical Officer asking prescribers to consider discontinuing the
high-risk medication along with a copy of the Beers criteria
article, a list of suggested alternatives to high-risk medica-
tions, and a list of older patients receiving the high-risk
medications who had upcoming appointments with these
prescribers.
MEASUREMENTS: The primary outcome was the ab-
sence of prescribed high-risk medications for all patients in
the cohort during the postintervention period. For a sub-
group of the cohort whose prescribers received the second-
stage intervention, an additional outcome was the absence
of prescribed high-risk medications within the subgroup.
RESULTS: Two thousand seven hundred fifty-three unique
patients were identified in the cohort; 1,396 (50.7%) had
high-risk medications discontinued, resulting in a signifi-
cant decrease in the number of patients prescribed high-risk
medications from the preintervention period to the postin-
tervention period (Po.001). Of the 801 patients in the
subgroup, 72.0% (n 5 577) had high-risk medications dis-
continued (Po.001).
CONCLUSION: This multimethod intervention signifi-
cantly decreased prescribing of high-risk medications to
older patients. Further studies are needed to confirm the
findings. J Am Geriatr Soc 56:1299–1305, 2008.
Key words: Beers criteria; medication prescribing; geri-
atrics; medication safety
With the aging of the population and the introductionof more-complex healthcare technologies, the med-
ical care of elderly people now demands significant effort
and resources in health systems throughout the world. One
area of increasing concern is the potential toxicities of
pharmacological agents used to treat a variety of disorders.
In addition to the known side effects of appropriately pre-
scribed drugs is the problem of prescribed agents that, be-
cause of age-related toxicities, are inappropriate for use in
an older population and are often responsible for significant
morbidity and mortality and higher healthcare costs. The
Institute of Medicine has suggested that workable solutions
must be found to improve unsafe medication practices, de-
crease drug-related problems, and improve patient safety.1
Adverse drug events have been linked to preventable
problems in elderly patients such as depression, constipa-
tion, falls, immobility, delirium, confusion, and hip frac-
tures. In community-dwelling elderly people, there is a high
prevalence of inappropriate medication use. Several criteria
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and indices have been used to quantify the extent of inap-
propriate use, and reports have observed rates of 20% to
30%.2–8 The widely cited Beers criteria were developed
from expert consensus in 1991 for just such a purpose and
were updated in 1997 and 2003.9–11 The Beers criteria have
been applied to develop an evidence-based list of medica-
tions that disproportionably place elderly patients at high-
risk for adverse drug events in light of the availability of
safer alternatives. Within the Veterans Affairs (VA) health
system, a recent examination of medication databases re-
vealed that 23% to 33% of all veterans aged 65 and older
had received a potentially inappropriate medication during
fiscal year 2000, as judged according to the Beers criteria.12
The key to successful use of criteria such as the Beers
criteria for improving medical care involves changing pre-
scribing behaviors. Modification of prescribing has been
achieved with variable success in many settings, using tech-
niques including formulary restrictions, collaborative care,
academic detailing, broad educational efforts, and
computerized alerts.13–22 Recent studies demonstrated that
implementation of computerized alerts could reduce pre-
scriptions for potentially inappropriate medications to
elderly patients.17,18 In the current study, a multimethod
quality improvement intervention, using a combination of
computerized alerts and personalized messages, was used to
change prescribing of selected high-risk medications within
a region of the VA health system.
METHODS
Study Setting
The Veterans Health Administration (VHA), within the
U.S. Department of Veterans Affairs, is the largest integrat-
ed healthcare system in the country. It is organized into 21
regional networks (called Veterans Integrated Service Net-
works (VISNs)) and provides a unique opportunity for
studying and implementing provider behavior change. Pro-
viders are employees of the health system, allowing for close
administrative oversight, and the VA’s information technol-
ogy systems allow access to aggregate and provider-specific
medical records, scheduling, and pharmacy data. VISN 11
is the VA regional network that consists of eight hospitals
and 21 freestanding, community-based outpatient clinics in
lower Michigan, most of Indiana, central regions of Illinois,
and northeastern Ohio. As part of its ongoing efforts at
quality improvement, VISN 11 undertook a network-wide,
multimethod intervention aimed at reducing prescriptions
for older veterans of five medications deemed ‘‘high risk’’
according to the Beers criteria.
Study Design
A pre- and postintervention design was used to evaluate the
effectiveness of a two-stage intervention aimed at reducing
prescription of five high-risk medications. The study re-
ceived exemption status from the VA institutional review
board.
Study Population
Although prescribers were the target of the two-stage in-
tervention (described below), a patient cohort was identi-
fied to examine prescription records related to five high-risk
medications of interest (Figure 1). The patient population
from which the cohort was selected consisted of all primary
care ambulatory veteran outpatients within VISN 11 aged
65 and older during the second and third quarters of 2004
(n 5 85,725). To be included in the cohort, patients had to
be receiving a prescription for one or more of the five high-
risk medications (n 5 2,753). Each prescriber who ordered
one of the high-risk medications for patients in this cohort
received the first-stage intervention. For the second-stage
intervention, a subgroup of patients in the cohort was iden-
tified. This subgroup included any patient in the cohort who
had a scheduled appointment at a VA ambulatory care set-
ting during the first 4 months of 2005 (n 5 801). Each pre-
scriber who was scheduled to see one or more patients in
the subgroup received the second stage of the intervention.
Intervention
Selection of the targeted medications began with an exam-
ination of prescription volume for all Beers criteria medi-
cations. Five commonly prescribed drugs were targeted for
the intervention and are operationally defined as ‘‘high risk’’
for purposes of this study: three tricyclic antidepressants
(amitriptyline, imipramine, and doxepin) and two ben-
zodiazepine sedative–hypnotics (chlordiazepoxide and
diazepam). All of these agents are included in the VA for-
mulary. These particular medications were selected based
on several criteria: They were being prescribed in a signifi-
cant portion of elderly patients in the VA population, they
are categorized as potentially inappropriate drugs and are
considered to have adverse outcomes of high severity ac-
cording to Beers, a preponderance of evidence suggests that
they should not be used in older patients,11,23,24 and one or
more therapeutic alternatives with a better safety profile are
readily available. There was consensus among the study
investigators involved in the selection process (AM, SC,
MS, PW, PR) that these five medications stood out from
the rest of the Beers list by virtue of the clear-cut evidence
Cohort 
All unique, ambulatory VISN 
11 patients, age ≥65, 
receiving any prescription 
during April to September 
2004 (n=85,725) 
Intervention
Primary study cohort, 




Real time, electronic alert
Subgroup of cohort, appointment
with prescriber of HR medication
January–April 2005
(n=801) 
Stage 2 Intervention 
Personalized letter, patient list 
with upcoming appointments, 
and education
Figure 1. Cohort identification and staged intervention.
VISN 5 Veterans Integrated Service Network. HR 5 high-risk
medications (amitriptyline, chlordiazepoxide, diazepam, doxe-
pin, imipramine).
1300 ZILLICH ET AL. JULY 2008–VOL. 56, NO. 7 JAGS
documenting their toxicity in older patients and that pri-
mary care physicians would generally agree that these med-
ications should be avoided in elderly people.
A two-stage intervention was implemented. The first
stage of the intervention, introduced in October 2004, was
a real-time medication-specific alert stating ‘‘not recom-
mended for patients over the age of 65’’ (Figure 2). The alert
appeared on the medication order screen of a patient’s elec-
tronic record whenever a prescriber ordered one of the five
high-risk drugs. The alert was provided in a generic infor-
mation field that is routinely used for a variety of other
drug-specific alerts. Once the warning had been activated in
the electronic medical record, every prescriber who was
ordering an outpatient prescription for one of the five high-
risk medications would receive this message. This warning
displayed to all clinicians writing for one of the high-risk
agents, independent of patient-specific criteria such as age.
The second-stage intervention linked administrative
patient appointment data with prescription data to target a
group of prescribers. These prescribers were chosen, because
they each had one or more upcoming appointments, during
the first 4 months of 2005, with one or more patients who
were receiving one or more high-risk medications. These
prescribers were specifically targeted, because they had the
greatest opportunity to change their prescribing behaviors
at a point in time close to the patient’s office visit. Each
targeted prescriber received a letter accompanied by a list of
patients with upcoming appointments. At the end of each
preceding month (i.e., in the final 10 days of December
2004 and January, February, and March 2005), a personally
addressed letter (Appendix A) that all of the hospital chiefs
of staff had reviewed, revised, and approved was sent, along
with an outline of the project, to each targeted prescriber
who was scheduled to see one or more patients during the
following months. The letter was sent from the Chief Med-
ical Officer of the VISN through the prescriber’s Chief of
Staff. The letter briefly described the rationale and goal of
the project. It notified recipients that they had been targeted
for the intervention, because they had written one or more
prescriptions for a high-risk medication for one or more
older patients who were scheduled to see them during the
coming month. The letter asked the recipients to consider
discontinuing or changing the medication and stated that
the prescribing of high-risk medications would be tracked
prospectively. There were no explicit incentives or penalties
to compel change in the prescribers’ behavior. There were
three attachments to the letter: a copy of the most recent
Beers criteria article,2 a list of suggested alternatives to each
of the high-risk medications, and a list of older patients
receiving one or more of the medications who had an ap-
pointment with the prescriber during the upcoming month.
Because each targeted prescriber was identified at the be-
ginning of each month of the intervention, prescribers could
each receive up to four letters according to the number of
months that they had appointments with patients during
this intervention. Prescribers did not receive a letter if they
did not prescribe any high-risk medications or did not
have an appointment during the intervention period with a
patient receiving a high-risk medication.
Data Collection, Outcomes, and Analyses
Preintervention data were collected before implementation
of the Stage 1 intervention, during the second (April–June)
and third (July–September) quarters of 2004 to identify
characteristics of the cohort. Postintervention data were
collected during the second and third quarters of 2005, after
implementation of the Stage 1 and Stage 2 interventions.
The primary outcome was the absence of a prescribed high-
risk medication for each patient in the cohort during the
postintervention period. The primary outcome focused on
the entire cohort for two reasons; this approach provided a
more conservative estimate of the effect of the intervention,
and the intervention may have had a carryover effect onto
prescribers that extended beyond the intervention period.
A secondary outcome examined the absence of a pre-
scribed high-risk medication for each patient in the sub-
group of the cohort. All electronic charts for the subgroup
were reviewed to evaluate changes in any high-risk pre-
scriptions. Using a standardized data abstraction form, two
trained research assistants each reviewed half of the charts
to ascertain whether the high-risk medication was contin-
ued, continued with a documented rationale for use,
changed to an alternative medication, or discontinued
during the clinic appointment. A study investigator (BH)
oversaw the chart review to ensure consistency between
reviewers and answer questions.
Other secondary analyses included a comparison of
changes in any high-risk medications for patients in the
subgroup with changes for patients who were in the cohort
but not part of the subgroup. This comparison was con-
ducted to compare patients who were exposed to the Stage
1 and Stage 2 interventions (subgroup) with those who were
exposed only to the Stage 1 intervention (remaining co-
hort). Additional analyses included the extent of prescribing
changes for each of the five high-risk medications.
The McNemars chi-square test for paired samples
compared changes in any high-risk medication from the
postintervention period to the preintervention period. Sep-
arate analyses for changes in individual medications were
also conducted using the McNemars test. All data were
analyzed using SPSS version 14.0 (SPSS Inc., Chicago, IL).
RESULTS
There were 2,753 unique patients identified in the cohort;
and 801 unique patients met inclusion criteria for the sub-Figure 2. Stage 1 intervention: Drug-specific real-time alert.
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group (those in the cohort who had at least one ambulatory
care appointment during the first 4 months of 2005) and
were available for follow-up chart review. There were 264
prescribers responsible for the high-risk prescriptions for
patients in the subgroup. These prescribers received an av-
erage of 2.2 letters during the second-stage intervention
period, for a total of 569 letters.
General characteristics of the identified cohort are list-
ed in Table 1. The cohort was predominantly older white
men. More than 70% of the cohort had hypertension, di-
abetes mellitus, or both. More than half of the patients in
the cohort had heart disease.
In the entire cohort, 50.7% of patients had the high-
risk medications discontinued, resulting in a significant de-
crease in the number of patients who were prescribed high-
risk medications from the preintervention period to the
postintervention period (Po.001). Of the 801 patients in
the subgroup, 72.0% (n 5 577) had one or more high-risk
medications discontinued (Po.001). In contrast, of the re-
maining 1,952 patients whose prescribers received only the
first intervention (i.e., real-time flag), 42.0% had high-risk
medications discontinued (Po.001).
Within the subgroup, high-risk medications were dis-
continued without replacement medication in 41.5%
(n 5 332) of patients and discontinued with a change to
an alternative agent in 30.6% (n 5 245) of patients. High-
risk medications were continued with documentation in
8.0% (n 5 64) of patients. The most common reasons for
continuation of a high-risk medication were ‘‘patient is sta-
ble on the medications and does not wish to change,’’ ‘‘pa-
tient was evaluated at this visit, and the provider feels that
the drug is appropriate at this time,’’ ‘‘patient denies any
harmful side effects,’’ ‘‘the medication is working well,’’
‘‘the patient does not want to try a new drug,’’ and ‘‘a new
drug may cause more problems.’’ In some instances, the
clinician expressed a concern about stopping the drug too
quickly and indicated that the drug dosage would be grad-
ually decreased over time (e.g., ‘‘veteran is amenable to re-
ducing doxepin from 50 mg to 25 mg and will consider
further discontinuation though reluctant given the number
of years of use. No dry mouth, constipation, or other side
effects reported.’’ Another example of reducing the dosage
was, ‘‘the patient has been on chlordioazepoxide for a long
time. The patient said he tried to go off Librium and he had
severe withdrawal effects but he is willing to taper off.’’
Table 2 shows the extent of changes in prescribing ac-
cording to medication. There was a significant decrease in
the number of patients prescribed all five medications from
the preintervention period to the postintervention period. In
addition, the table shows results for the medications ac-
cording to the level of intervention. In the group that re-
ceived only the first stage of the intervention, the range of
patients who were no longer prescribed high-risk medica-
tions was 30.2% to 48.0%. In the group that received the
first and second stages of the intervention, the range of pa-
tients no longer prescribed high-risk medication was 50.0%
to 78.4%. More than half of all opportunities (57%) for
changing high-risk medications were related to amitripty-
line. An additional 20% of all opportunities were related to
diazepam, 10% to doxepin, 7% to imipramine, and 6% to
chlordiazepoxide.
To assist in understanding the effect of the staged in-
tervention, the number of unique patients, aged 65 and
older receiving one or more of the five high-risk medications
during the year before implementation of the intervention
and during the year after completion of the intervention was
determined. On average, in the four quarters before the
Stage 1 intervention, there were 2,432 older patients who
received at least one of the five high-risk medications. In
the year after completion of the Stage 2 intervention, the
average number of patients who received at least one of
the five medications was 1,485: a 39% decrease. The Stage
1 intervention (real-time flag) continued to remain active
in the year after completion of the Stage 2 intervention,
although the absolute the number of unique patients who
received one or more high-risk medications remained fairly
constant during each quarter of that year (range 1,457–
1,501 patients).
DISCUSSION
This article reports on an effective intervention using a
combination of targeted education and administrative
oversight in reducing the number of older veterans in an
outpatient setting prescribed high-risk medications. This
result, when applied broadly, could have significant
cost and quality implications in the medical care of
elderly people.
Various interventions have been developed and tested to
reduce inappropriate medication use and improve evidence-
based prescribing. Strategies to alter prescribing practices
include academic detailing, broad educational outreach,
and computerized decision support.13,14,17–19,22,25,26 An
interrupted time series evaluation found that a drug-specific
alert reduced the percentage of patients receiving high-risk
medications 35% after controlling for baseline trend.18 In
Table 1. Characteristics of the Cohort (N 5 2,753)
Characteristic Value
Age, mean  SD 72.5  5.9





American Indian or Alaska Native 1 (0.04)
Missing or unknown 1,086 (39.5)
Comorbid conditions, n (%)w
Hypertension 2,357 (85.6)
Diabetes mellitus 2,000 (72.6)
Ischemic heart disease 1,645 (59.8)
Depression 653 (23.7)
Heart failure 391 (14.2)
Number of high-risk medications, mean  SD 1.02  0.15
Age as of the preintervention period (second and third quarters of 2004).
wComorbid conditions based on administrative International Classification of
Diseases, Ninth Revision, codes. Patients may have had more than one of the
comorbidities listed and, in addition, may have had comorbidities other than
the five abstracted for this study.
SD 5 standard deviation.
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the current study, the cohort that was exposed to the Stage 1
intervention (real-time computer alert) but not the Stage 2
intervention had a 45% reduction in prescriptions for high-
risk medications. In the previous study, the medications in-
cluded the same five examined in the current study plus
additional high-risk medications.18
Although the results from these two studies are similar,
there are several important things to consider. First, the
context and design of the computer alerts can influence the
findings. In both studies, the electronic alert was ‘‘drug
specific’’ not ‘‘patient specific.’’ As a result, the alert was
displayed every time a prescriber ordered one of the high-
risk medications. Patient-specific variables such as age were
not a factor in the display of the alert. This type of drug-
specific alert could increase prescriber burden and decrease
prescriber vigilance. A more-effective alert might incorpo-
rate drug- and patient-specific variables. Also, the design of
the alert varied in the two studies. In the previous study,
the drug alert included alternative medications on screen.18
With one step, the prescriber could order the alternative
medications, and to continue with the order for a high-risk
medication, the prescriber was required to perform an ad-
ditional step, whereas in the current study, the alert was
‘‘passive’’ and did not provide on-screen alternative med-
ications. Additional steps were required to order the alter-
native medications rather than continuing the order for the
high-risk medication. Given these differences in design, it
would be reasonable to expect that the alert in the previous
study would be more effective. The differences in results
between the two studies may be due to the number of med-
ications targeted, differences in the hospital systems (e.g.,
VA vs non-VA clinics), and differences in the structure and
function of the electronic health records.
The Stage 2 intervention in this study offered several
unique aspects that seemed to successfully change prescrib-
er behavior. First, using administrative data, a targeted
group of prescribers was identified to receive a personally
relevant educational letter. By targeting specific prescribers,
this intervention focused on those clinicians with the great-
est opportunity to change prescribing behavior (e.g., a pre-
scriber with no recent history of prescribing high-risk
medications would be less likely to be affected), thereby
reducing resource requirements and increasing the bene-
fit:cost ratio of the intervention.
Second, along with the letter, the targeted group received
a list of patients for whom the prescriber would soon have a
convenient opportunity to affect with the new knowledge.
Prescriber learning often occurs from consultations with
colleagues who provide knowledge that can be directly
applied to specific patients during the office visit.27–29
Therefore, the intervention in this study was designed to
educate prescribers at a point in time close to the patient’s
office visit. Clinicians could apply the knowledge gained
from the intervention to relevant patients who were sched-
uled to be seen in the upcoming month. In addition, the
education may carry over to affect other patients seen by the
prescriber at a later date.
Third, the intervention was focused on a limited num-
ber of specific medications from the Beers list. There was
consensus among the study physicians that these five med-
ications stood out from the rest of the Beers list by virtue of
the clear-cut evidence documenting their toxicity in older
patients and the availability of less-harmful alternative
medications. Including only these five medications limited
the scope of the intervention and also avoided questions
that may have arisen regarding some medications on the




Entire cohort (any high-risk medication)w 2,753 1,357  50.7
Amitriptyline 1,608 729  54.7
Chlordiazepoxide 160 86  46.3
Diazepam 556 303  45.5
Doxepin 288 160  44.5
Imipramine 208 113  45.7
Stage 1 intervention only (any high-risk medication) 1,952 1,133  42.0
Amitriptyline 1,149 598  48.0
Chlordiazepoxide 109 75  31.2
Diazepam 377 263  30.2
Doxepin 210 137  34.8
Imipramine 168 93  44.6
Stage 1 and 2 intervention (any high-risk medication) 801 224  72.0
Amitriptyline 459 132  71.2
Chlordiazepoxide 51 11  78.4
Diazepam 179 40  77.7
Doxepin 78 23  70.5
Imipramine 40 20  50.0
All pre–post comparisons were significant at Po.001.
wPrescribers in the entire cohort received a combination of the Stage 1 intervention only or the Stage 1 intervention plus the Stage 2 intervention. Any high-risk
medication refers to the medications listed in the table.
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Beers list for which controversy exists or where exceptions
for use of the medication are more common.
Finally, the letter was generated and signed with ad-
ministrative support from colleagues. To be most effective,
prescriber education should be conducted by someone
viewed as a colleague or opinion leader.30 In this study, the
educational letter was generated after several revisions from
the Medical Chiefs of Staff and sent by the VISN Chief
Medical Officer (CMO). In general the VISN CMO and the
Chief of Staff are physician colleagues who other clinicians
may view as opinion leaders. In addition, there is the pos-
sibility that the information, coming from the CMO of the
healthcare system, along with the knowledge that future
prescribing of these agents would be tracked, may also carry
some element of performance expectation.
Although the results of this quality improvement pro-
ject are intriguing, there are several limitations. First, there
was no control group identified for this project, because it
was designed for quality improvement rather than a rigor-
ous test of an intervention. Therefore, the study cannot ac-
count for changes that would occur because of regression to
the mean, temporal trends, or other factors occurring dur-
ing the intervention period. It is possible that similar re-
ductions in the number of patients prescribed high-risk
medications occurred despite this intervention, although
the magnitude of the reduction suggests otherwise. In ad-
dition, the number of unique patients who were receiving
one or more high-risk medications was relatively flat during
the year before the intervention. Nevertheless, future stud-
ies should include a control group to provide a more-
accurate estimate of the effect. Also, the intervention was
twofold, and the second stage contained several compo-
nents (two educational pieces, a request by an authority
figure to change prescribing, and patient information to
facilitate compliance with the request). The study design
was not able to determine which part or parts of the inter-
ventions were more successful, although it appears that the
components of the second-stage intervention may have been
more successful given that much-larger decreases in the
number of patients prescribed high-risk medications was
seen in the subgroup that received both stages of the inter-
vention than in the subgroup that received only the first
stage of the intervention. In addition, the number of unique
patients who were receiving one or more high-risk medi-
cations was relatively flat during the year after completion
of the second-stage intervention while the first stage inter-
vention continued. Although the interventions were target-
ed at prescribers, no data were collected on prescriber
characteristics. Ideally, these data would provide informa-
tion useful for predicting response to other interventions.
Future studies should include data on prescribers to allow
targeting in future interventions. Finally, this study used a
combination of healthcare information technology and in-
frastructure within a regional VA system. Although the in-
tervention may be replicable at other VA systems, it may be
less easily generalized to other non-VA healthcare systems
that lack the ability to link outpatient medications, pre-
scriber identities, and outpatient appointments. Neverthe-
less, as healthcare systems increase their information
technology resources, approaches such as this one, linking
administrative and clinical data sources, will become in-
creasingly feasible.
The multimethod intervention in this study reduced the
prescribing of high-risk medications to older veterans by
50%. These findings should be confirmed in future studies
using a control group and in non-VA settings. If effective,
this intervention could have significant quality and cost
implications in the medical care of older adults.
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Appendix A
Date:  Date 
From: Chief Medical Officer, VISN 11 (10N11)
Subj: Reduction in use of ‘‘Potentially Inappropriate Medications’’ in outpatient
veterans over age 65 in VISN 11.
To:  Name of Provider 
THRU: Chief of Staff (11)  signature 
1. As part of the ongoing effort to continuously improve the quality of care of
veterans in VISN 11, steps are underway to reduce or even to eliminate the
use of certain pharmacological agents that have been shown in patients
over age 65 to have less or equivalent efficacy yet a less favorable side-
effect profile, compared to other agents. This memorandum urges your
support in this effort.
2. Attached for your consideration is a review article on ‘‘Potentially Inappro-
priate Medications for use in the Elderly’’ from Archives of Internal Medicine.
My office, in collaboration with the VISN 11 Geriatrics & Extended
Care Service Line, is initially focusing on reducing or eliminating the use in






3. Pharmacy records indicate that you wrote one or more prescriptions for one
or more of these agents during the third and fourth quarters of FY04. To
support your efforts to limit the use of these agents in older patients in the
future, attached is a list of over-age-65 patient(s) for whom you prescribed
one or more of the preceding agents; and who are appointed to see you
during January 2005. You are encouraged to select an alternative agent
for these patients at the times of their next appointments (a third
attachment to this letter identifies those agents suggested as preferable
alternatives by the VISN’s Pharmacy Benefits Manager). You are also re-
quested to not write new prescriptions for any of these agents to any
veteran over age 65.
4. To further assist this process, as of January 1 prescription orders in CPRS
for these agents will receive a warning that they are ‘‘potentially inappro-
priate for patients over age 65 years.’’
5. You will receive a memorandum similar to this, accompanied by a list of
patients already receiving these agents who are scheduled to see you the
following month, each month through May (excepting any month in which
no such patients are scheduled to see you). Prescribing patterns within the
medical center, and in VISN 11, will be assessed at that time relative to
FY04. It is our hope and expectation that prescriptions of these agents to
veterans over age 65 will show a significant decline. If this is not the case,
alternative approaches to achieving the desired end will be considered.
6. The Institute of Medicine has estimated that adverse drug reactions cost
over $100 billion annually in the U.S. You are being asked to do your part to
curb those adverse effects in a small but particularly vulnerable subgroup
of your clinical population. The success of the approach is dependent
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